- Home
- CAPR vs MIN Comparison
CAPR vs MIN Comparison
Compare CAPR & MIN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CAPR
- MIN
- Stock Information
- Founded
- CAPR 2005
- MIN 1988
- Country
- CAPR United States
- MIN United States
- Employees
- CAPR N/A
- MIN N/A
- Industry
- CAPR Biotechnology: Biological Products (No Diagnostic Substances)
- MIN Trusts Except Educational Religious and Charitable
- Sector
- CAPR Health Care
- MIN Finance
- Exchange
- CAPR Nasdaq
- MIN Nasdaq
- Market Cap
- CAPR 324.6M
- MIN 302.7M
- IPO Year
- CAPR N/A
- MIN N/A
- Fundamental
- Price
- CAPR $6.28
- MIN $2.68
- Analyst Decision
- CAPR Strong Buy
- MIN
- Analyst Count
- CAPR 8
- MIN 0
- Target Price
- CAPR $24.75
- MIN N/A
- AVG Volume (30 Days)
- CAPR 1.4M
- MIN 331.0K
- Earning Date
- CAPR 08-11-2025
- MIN 01-01-0001
- Dividend Yield
- CAPR N/A
- MIN 7.31%
- EPS Growth
- CAPR N/A
- MIN N/A
- EPS
- CAPR N/A
- MIN 0.08
- Revenue
- CAPR $13,392,150.00
- MIN N/A
- Revenue This Year
- CAPR N/A
- MIN N/A
- Revenue Next Year
- CAPR $6,061.53
- MIN N/A
- P/E Ratio
- CAPR N/A
- MIN $33.38
- Revenue Growth
- CAPR N/A
- MIN N/A
- 52 Week Low
- CAPR $3.98
- MIN $2.52
- 52 Week High
- CAPR $23.40
- MIN $2.88
- Technical
- Relative Strength Index (RSI)
- CAPR 36.33
- MIN 49.09
- Support Level
- CAPR $6.17
- MIN $2.65
- Resistance Level
- CAPR $7.30
- MIN $2.71
- Average True Range (ATR)
- CAPR 0.43
- MIN 0.03
- MACD
- CAPR -0.11
- MIN -0.00
- Stochastic Oscillator
- CAPR 4.53
- MIN 41.67
About CAPR Capricor Therapeutics Inc.
Capricor Therapeutics Inc is a clinical-stage biotechnology company focused on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (DMD), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with high unmet medical needs. The company's product pipeline includes CAP-1002, deramiocel an allogeneic cardiac-derived cell therapy. Deramiocel is currently advancing through Phase 3 clinical development for the treatment of Duchenne muscular dystrophy. Through its proprietary StealthXTM platform, the group uses its exosome technology to conduct preclinical research focused on vaccinology, delivering oligonucleotides, proteins, and small molecules to treat.
About MIN MFS Intermediate Income Trust
MFS Intermediate Income Trust is a diversified closed-end management investment company. The fund's investment objective is to seek high current income but may also consider capital appreciation. It invests the assets in debt instruments. Its portfolio of investments comprises of different sector investments such as the automotive, chemicals, energy, food and beverages, insurance, and other sectors.